Proteomics in pancreatic cancer
Abstract Pancreatic cancer (PC), one of the most aggressive malignancies, is characterized by a dismal prognosis owing to its low early detection rates, rapid progression, frequent postoperative complications, and limited efficacy of conventional oncological therapies. The fact that most patients ar...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-025-00805-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849763961553027072 |
|---|---|
| author | Fei Cai Yufan Gu Yingying Ling Guanhua Yi Shengze Zang Tao Su Yueqiu Liu Ang Li Denian Wang Wanjun Zhao Xinfang Xie Guisen Li Lunzhi Dai Meng Gong Hao Yang Yang Zhao Yong Zhang |
| author_facet | Fei Cai Yufan Gu Yingying Ling Guanhua Yi Shengze Zang Tao Su Yueqiu Liu Ang Li Denian Wang Wanjun Zhao Xinfang Xie Guisen Li Lunzhi Dai Meng Gong Hao Yang Yang Zhao Yong Zhang |
| author_sort | Fei Cai |
| collection | DOAJ |
| description | Abstract Pancreatic cancer (PC), one of the most aggressive malignancies, is characterized by a dismal prognosis owing to its low early detection rates, rapid progression, frequent postoperative complications, and limited efficacy of conventional oncological therapies. The fact that most patients are diagnosed at advanced stages underscores the critical importance of early detection for the formulation of effective treatment strategies. Despite substantial research efforts, the medical community still lacks consistent and dependable biomarkers for the diagnosis, classification, and prognosis of PC, highlighting the urgent need for innovative and more efficient approaches to identify pancreatic abnormalities at early stages. For decades, mass spectrometry (MS)-based proteomics has been extensively applied in disease diagnostics, mechanistic investigations, and screening of potential drug targets. This review systematically synthesizes recent advancements in clinical proteomic techniques and applications, highlighting significant biomarker discoveries and signal transduction networks associated with PC. By integrating these findings, we provide novel insights into the molecular mechanisms underlying PC development and progression, which may facilitate the identification of new diagnostic biomarkers and therapeutic targets for this disease. |
| format | Article |
| id | doaj-art-86c0d2efed44471da63afb892115d60f |
| institution | DOAJ |
| issn | 2050-7771 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Biomarker Research |
| spelling | doaj-art-86c0d2efed44471da63afb892115d60f2025-08-20T03:05:16ZengBMCBiomarker Research2050-77712025-07-0113114310.1186/s40364-025-00805-yProteomics in pancreatic cancerFei Cai0Yufan Gu1Yingying Ling2Guanhua Yi3Shengze Zang4Tao Su5Yueqiu Liu6Ang Li7Denian Wang8Wanjun Zhao9Xinfang Xie10Guisen Li11Lunzhi Dai12Meng Gong13Hao Yang14Yang Zhao15Yong Zhang16Department of Pancreatic Surgery and Institutes for Systems Genetics, West China Hospital, Sichuan UniversityDepartment of Pancreatic Surgery and Institutes for Systems Genetics, West China Hospital, Sichuan UniversityDepartment of Pancreatic Surgery and Institutes for Systems Genetics, West China Hospital, Sichuan UniversityDepartment of Pancreatic Surgery and Institutes for Systems Genetics, West China Hospital, Sichuan UniversityDepartment of Pancreatic Surgery and Institutes for Systems Genetics, West China Hospital, Sichuan UniversityDepartment of Pancreatic Surgery and Institutes for Systems Genetics, West China Hospital, Sichuan UniversityDepartment of Pancreatic Surgery and Institutes for Systems Genetics, West China Hospital, Sichuan UniversityDepartment of Pancreatic Surgery and Institutes for Systems Genetics, West China Hospital, Sichuan UniversityPrecision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan UniversityDivision of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan UniversityDepartment of Nephrology, The First Affiliated Hospital of Xi’an Jiaotong UniversityRenal Department, Institute of Nephrology, Sichuan Provincial People’s Hospital, Sichuan Clinical Research Center for Kidney Diseases, University of Electronic Science and Technology of ChinaNational Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan UniversityDepartment of Pancreatic Surgery and Institutes for Systems Genetics, West China Hospital, Sichuan UniversityTransplant Center and NHC Key Lab of Transplant Engineering and Immunology, West China Hospital, Sichuan UniversityTechnology Innovation Center of Mass Spectrometry for State Market Regulation, Center for Advanced Measurement Science, National Institute of MetrologyDepartment of Pancreatic Surgery and Institutes for Systems Genetics, West China Hospital, Sichuan UniversityAbstract Pancreatic cancer (PC), one of the most aggressive malignancies, is characterized by a dismal prognosis owing to its low early detection rates, rapid progression, frequent postoperative complications, and limited efficacy of conventional oncological therapies. The fact that most patients are diagnosed at advanced stages underscores the critical importance of early detection for the formulation of effective treatment strategies. Despite substantial research efforts, the medical community still lacks consistent and dependable biomarkers for the diagnosis, classification, and prognosis of PC, highlighting the urgent need for innovative and more efficient approaches to identify pancreatic abnormalities at early stages. For decades, mass spectrometry (MS)-based proteomics has been extensively applied in disease diagnostics, mechanistic investigations, and screening of potential drug targets. This review systematically synthesizes recent advancements in clinical proteomic techniques and applications, highlighting significant biomarker discoveries and signal transduction networks associated with PC. By integrating these findings, we provide novel insights into the molecular mechanisms underlying PC development and progression, which may facilitate the identification of new diagnostic biomarkers and therapeutic targets for this disease.https://doi.org/10.1186/s40364-025-00805-yPancreatic cancerPancreatic ductal adenocarcinomaProteomicsMass spectrometryBiomarkers |
| spellingShingle | Fei Cai Yufan Gu Yingying Ling Guanhua Yi Shengze Zang Tao Su Yueqiu Liu Ang Li Denian Wang Wanjun Zhao Xinfang Xie Guisen Li Lunzhi Dai Meng Gong Hao Yang Yang Zhao Yong Zhang Proteomics in pancreatic cancer Biomarker Research Pancreatic cancer Pancreatic ductal adenocarcinoma Proteomics Mass spectrometry Biomarkers |
| title | Proteomics in pancreatic cancer |
| title_full | Proteomics in pancreatic cancer |
| title_fullStr | Proteomics in pancreatic cancer |
| title_full_unstemmed | Proteomics in pancreatic cancer |
| title_short | Proteomics in pancreatic cancer |
| title_sort | proteomics in pancreatic cancer |
| topic | Pancreatic cancer Pancreatic ductal adenocarcinoma Proteomics Mass spectrometry Biomarkers |
| url | https://doi.org/10.1186/s40364-025-00805-y |
| work_keys_str_mv | AT feicai proteomicsinpancreaticcancer AT yufangu proteomicsinpancreaticcancer AT yingyingling proteomicsinpancreaticcancer AT guanhuayi proteomicsinpancreaticcancer AT shengzezang proteomicsinpancreaticcancer AT taosu proteomicsinpancreaticcancer AT yueqiuliu proteomicsinpancreaticcancer AT angli proteomicsinpancreaticcancer AT denianwang proteomicsinpancreaticcancer AT wanjunzhao proteomicsinpancreaticcancer AT xinfangxie proteomicsinpancreaticcancer AT guisenli proteomicsinpancreaticcancer AT lunzhidai proteomicsinpancreaticcancer AT menggong proteomicsinpancreaticcancer AT haoyang proteomicsinpancreaticcancer AT yangzhao proteomicsinpancreaticcancer AT yongzhang proteomicsinpancreaticcancer |